Hua Medicine (Shanghai) Ltd. (HKG:2552)

Market Cap	2.23B -53.4%
Revenue (ttm)	755.49M +76.6%
Net Income	-124.44M
EPS	-0.13
Shares Out	998.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,379,500
Open	2.295
Previous Close	2.290
Day's Range	2.180 - 2.310
52-Week Range	1.970 - 4.820
Beta	0.81
Analysts	Strong Buy
Price Target	4.52 (+102.69%)
Est. Earnings	Nov 20, 2026

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 424
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2552

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 2552 stock is "Strong Buy." The 12-month stock price target is $4.52, which is an increase of 102.69% from the latest price.

Price Target

$4.52

(102.69% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error